Pcn188 - Assessing the Robustness of a Cost-Effectiveness Analysis of Lenvatinib Versus Sorafenib in Unresectable Hepatocellular Carcinoma in Japan

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.270
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Lenvatinib and Its Use in the Treatment of Unresectable Hepatocellular Carcinoma

Future Oncology
MedicineCancer ResearchOncology
2018English

Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Pcn168 - Cost-Effectiveness of Sorafenib in the Treatment of Hepatocellular Carcinoma: A Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Overall Survival in Response to Sorafenib Versus Radiotherapy in Unresectable Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis: Propensity Score Analysis

BMC Gastroenterology
MedicineGastroenterology
2014English

Retrospective Analysis of Transarterial Chemoembolization and Sorafenib in Chinese Patients With Unresectable and Recurrent Hepatocellular Carcinoma

Oncotarget
Oncology
2016English

Sorafenib Continuation or Discontinuation in Patients With Unresectable Hepatocellular Carcinoma After a Complete Response

Oncotarget
Oncology
2015English

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

Yttrium-90 Radioembolization Versus Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Comparative Analysis

HPB
HepatologyGastroenterology
2016English

Efficacy and Adverse Events of Transcatheter Arterial Chemoembolization in Combination With Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma

Molecular and Clinical Oncology
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy